Source: The Economic Times, May 04, 2012
MUMBAI: Abbott Laboratories will collaborate with Bangalore-based Biocon to establish a research and development centre to develop nutrition products in India.
Abbott Nutrition Centre, India will work with Syngene, the contract research arm of Biocon, to develop affordable products for maternal, child nutrition and diabetes care, the companies said in a joint press release.
Source: The Hindu Business Line, Mar 06, 2012
Chennai: The healthcare industry has urged the Government to provide the required stimulus that will make the industry attractive to investors.
Dr Prathap Reddy, Chairman, Apollo Hospitals said: “There is a huge demand-supply gap in healthcare services. Around Rs 60,000 crore has to be invested each year for the next 10 years to expand bed strength. We also need more hospitals, labs and operation theatres. We are not asking funds or grants but we need no-strings-attached stimulus to attract long-term investments in the form of equity or debt.”
Source: The Hindu Business Line, Mar 04, 2012
Gurgaon: To promote medical tourism in Haryana, the State government has decided to accord the status of industry to health sector projects with investments of or above Rs 100 crore.
“The government has decided to give the status of industry to the projects with investments of Rs 100 crore or more in health sector,” said the Haryana Health Minister, Mr Rao Narender Singh.
The State government is also exploring possibilities of developing Haryana as a centre of medical tourism and necessary provisions have been made in the new Industrial and Investment Policy 2011, Mr Singh said.
Source: Business standard, Mar 01, 2012
New Delhi: The Prime Minister’s Office (PMO) has chalked out a multi-pronged strategy to increase government spending on health — to 2.5 per cent of the gross domestic product by the end of the 12th Plan (2012-2017) from — current 1.4 per cent, besides steps to incentivise states for increased expenditure in this critical area.
Source: The Economic Times, Jan 25, 2012
NEW DELHI: As many as 250 top executives of UK-based GSK Consumer Healthcare, led by its President Emma Walmsley, will fly down to Delhi in early February for an annual leadership meet, its first such conclave outside the UK and US, throwing the spotlight on India’s emergence as one of the fastest-growing consumer markets of the world.
Read the rest of this entry »
Source: The Economics Times, Jan 14, 2012
NEW DELHI: Promising a new dimension to the future of robotic surgery in the country, India will soon be getting its first training centre for the technique, a robotic surgery firm said here Saturday.
Source: The Economics Times, Jan 09, 2012
NEW DELHI: Small speciality hospitals and centres are acquiring latest equipment and technology, investing a significant portion of their annual sales in a single machine to specialise in their niche areas in order to attract high-end customers from corporate hospital.
Source: The Economic Times, Dec 15, 2011
MUMBAI: India’s low rate of diagnosis and disease awareness presents ample opportunity for drug makers to do more in the country, Vivek Mohan, managing director, Abbott India, said.
Abbott which is a leader in branded generics in India is also betting big on the diognostics business “Diagnostics is one of the most important parts of diversified diagnosis business. We are trying to create presence that is strong to the needs of India,” Mohan told ET in an interview.
Source: The Economic Times, Nov 25, 2011
MUMBAI: Apollo Hospitals Enterprise said on Wednesday it plans to launch 100 clinics dedicated to treat diabetes across India in three months.
The clinics would work on a specifically developed Clinical pathway and offer standardised care to the diabetic patients, it said in a statement.
“Keeping in mind the rising burden of diabetes, India would need an integrated framework that would enable diabetics manage their lifestyle better,” Chairman Prathap Reddy was quoted as saying in the statement.
Source: Business standard, Nov 18, 2011
New Delhi: The health ministry is planning to develop a foolproof mechanism to ensure recall of all faulty and banned drugs from the Rs 60,000-crore domestic pharmaceutical market.
The move will strengthen the existing recall provisions under the Drugs and Cosmetic Rules. The current law, however, fails to prescribe time-bound recall formats.
